LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Novavax Inc

Затворен

СекторЗдравеопазване

8.89 -1

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.85

Максимум

9.33

Ключови измерители

By Trading Economics

Приходи

-27M

-9.5M

Продажби

-7.6M

140M

P/E

Средно за сектора

3.112

50.958

EPS

-0.06

Марж на печалбата

-6.803

Служители

749

EBITDA

-29M

-543K

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+44.16% upside

Дивиденти

By Acuity

Следващи печалби

5.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

160M

1.5B

Предишно отваряне

9.89

Предишно затваряне

8.89

Настроения в новините

By Acuity

56%

44%

275 / 342 Класиране в Healthcare

Novavax Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Относно Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
help-icon Live chat